title: Second-Generation Drug-Eluting Balloon for Ostial Side Branch Lesions (001-Bifurcations): Mid-Term Clinical and Angiographic Results.
abstract: In the drug-eluting stent era, the best strategy to treat Medina 001 lesion remains unestablished. This is the first prospective registry assessing the efficacy and safety of the second-generation drug-coated balloon in patients with side-branch ostial lesion.
  
  
  
  Forty-nine patients with de novo Medina 001 lesion and associated myocardial ischemia were treated with second-generation drug-coated balloon-Dior balloon catheter (Eurocor GmbH, Bonn Germany), and prospectively included in this study. After mandatory pre-dilatation, a paclitaxel-eluting balloon was inflated for a minimum of 45 seconds. Left main bifurcation, severely calcified lesions and cardiogenic shock, were the only exclusion criteria.
  
  
  
  The inclusion period was 2.7 years. Mean age was 62 ± 12 years old, 41% diabetic, 65% presented with acute coronary syndrome. The most common vessel treated was the first diagonal (50%). Pre-dilatation with a cutting balloon was used in 59%. Angiographic success was 86% (in 14% a bare metal stent was implanted because of acute recoil [n = 5] or coronary dissection more than type B [n = 2]). At a mean of 12.2 ± 2.2 months, major cardiac adverse events rate was 14.3% (1 myocardial infarction, 0 cardiac deaths, 7 target lesion revascularization). There was no thrombosis or occlusion. At a mean of 7.2 ± 1.1 months, binary restenosis was 22.5% (n = 7) with a late loss of 0.32 ± 0.73 mm.
  
  
  
  Medina 001 lesion is an infrequent type of coronary lesion. Drug-coated balloon-Dior is a safe and technically easy therapeutic option, associated with acceptable mid-term clinical outcomes. (J Interven Cardiol 2016;29:285-292).
authors.affiliation: Interventional Cardiology Unit, Hospital del Mar, Barcelona, Spain.|Interventional Cardiology Unit, Hospital Sant Pau, Barcelona, Spain.
authors.forename: Beatriz
authors.initials: B
authors.lastname: Vaquerizo
authors.affiliation: Interventional Cardiology Unit, Hospital Trias i Pujol, Barcelona, Spain.
authors.forename: Eduardo
authors.initials: E
authors.lastname: Fernández-Nofreiras
authors.affiliation: Interventional Cardiology Unit, Hospital Vall Hebron, Barcelona, Spain.
authors.forename: Inmanol
authors.initials: I
authors.lastname: Oategui
authors.affiliation: Interventional Cardiology Unit, H. Reina Sofia, Córdoba, Spain.
authors.forename: Javier
authors.initials: J
authors.lastname: Suarez de Lezo
authors.affiliation: Interventional Cardiology Unit, Hospital Galdakao, Galdakao, Spain.
authors.forename: José Ramón
authors.initials: JR
authors.lastname: Rumoroso
authors.affiliation: Interventional Cardiology Unit, H. Dr. Negrín, Gran Canaria, Spain.
authors.forename: Pedro
authors.initials: P
authors.lastname: Martín
authors.affiliation: Department of Cardiology, Worcestershire Royal Hospital, Worcester, UK.
authors.forename: Helen
authors.initials: H
authors.lastname: Routledge
authors.affiliation: Interventional Cardiology Unit, Hospital del Mar, Barcelona, Spain.
authors.forename: Helena
authors.initials: H
authors.lastname: Tizón-Marcos
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000379:methods*; D017023:Coronary Angiography / Q000009:adverse effects / Q000379:methods*; D003324:Coronary Artery Disease / Q000601:surgery*; D054855:Drug-Eluting Stents; D005260:Female; D005858:Germany; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000627:therapeutic use*; D011446:Prospective Studies; D012042:Registries; D016896:Treatment Outcome
chemical_list: D017239:Paclitaxel